Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Childhood Cancers

The Division of Hematology and Oncology at Monroe Carell Jr. Children's Hospital at Vanderbilt includes a dedicated faculty and staff who work together as a team in the diagnosis and treatment of children with cancer or blood diseases. The division also supports a variety of clinical and research programs, a consultation service, and a fellowship training program.

Clinical Trials for Pediatric Cancers

22 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

COGAHOD04B1

10/05/2011

AHOD04B1 - Hodgkin Disease (HD) Banking Study

Basic Science

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

COGAALL05B1

12/01/2006

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Basic Science

COGANHL04B1

09/14/2006

Rare and Cutaneous Non-Hodgkin Lymphoma Registry

Diagnostic

VICCSAR1275

03/21/2013

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Health Services Research

VICCREACH1447

04/16/2014

Retinoblastoma Survivor Study (RBSS)

Other

VICCPED0995

02/18/2010

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Other

VICCPED0974

09/10/2009

Avoidance of Sun Exposure in Patients who Have Had Allogenic Stem Cell Transplants: Effects on Vitamin D Levels and Bone Turnover Markers

Other

VICCPED0710

03/16/2007

Long Term Effects for Childhood Cancer Survivors

Other

COGALTE03N1

04/20/2005

Key Adverse Events after Childhood Cancer

Prevention

VICCPED12112

01/04/2013

NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Supportive Care

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Supportive Care

VICCPED0921

05/01/2009

Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD.

Treatment

VICCSAR1419

08/27/2014

A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

Treatment

COGANBL1232

08/20/2014

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Treatment

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Treatment

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Treatment

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum

Treatment

COGACNS0821

10/08/2011

ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Treatment

COGACNS0831

05/12/2011

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.

Treatment

COGAALL0932

11/11/2010

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Treatment

COGAALL0631

09/09/2008

A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy =/+ FLT3 Inhibition